Literature DB >> 34020488

Adherence to the 'Atrial Fibrillation Better Care' Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients.

Giulio Francesco Romiti1,2, Daniele Pastori3, José Miguel Rivera-Caravaca1,4, Wern Yew Ding1, Ying Xuan Gue1, Danilo Menichelli3, Jakub Gumprecht1,5, Monika Kozieł1,5, Pil-Sung Yang6, Yutao Guo7, Gregory Y H Lip1,8, Marco Proietti1,9,10.   

Abstract

OBJECTIVE: The 'Atrial fibrillation Better Care' (ABC) pathway has been recently proposed as a holistic approach for the comprehensive management of patients with atrial fibrillation (AF). We performed a systematic review of current evidence for the use of the ABC pathway on clinical outcomes. METHODS AND
RESULTS: We performed a systematic review and meta-analysis according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. PubMed and EMBASE were searched for studies reporting the prevalence of ABC-pathway-adherent management in AF patients, and its impact on clinical outcomes (all-cause death, cardiovascular death, stroke, and major bleeding). Meta-analysis of odds ratio (OR) was performed with random-effects models; subgroup analysis and meta-regression were performed to account for heterogeneity. Among the eight studies included, we found a pooled prevalence of ABC-adherent management of 21% (95% confidence interval, CI: 13-34%), with a high grade of heterogeneity, explained by the increasing adherence to each ABC criterion. Patients treated according to the ABC pathway showed a lower risk of all-cause death (OR: 0.42; 95% CI: 0.31-0.56), cardiovascular death (OR: 0.37; 95% CI: 0.23-0.58), stroke (OR: 0.55; 95% CI: 0.37-0.82) and major bleeding (OR: 0.69; 95% CI: 0.51-0.94), with moderate heterogeneity. Prevalence of comorbidities was moderators of heterogeneity for all-cause and cardiovascular death, while longer follow-up was associated with increased effectiveness for all outcomes.
CONCLUSION: Adherence to the ABC pathway was suboptimal, being adopted in one in every five patients. Adherence to the ABC pathway was associated with a reduction in the risk of major adverse outcomes. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34020488     DOI: 10.1055/a-1515-9630

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   6.681


  40 in total

1.  The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort.

Authors:  Gregory Y H Lip; Francisco Marín; José Miguel Rivera-Caravaca; Vanessa Roldán; Lorena Martínez-Montesinos; Vicente Vicente
Journal:  J Gen Intern Med       Date:  2022-04-11       Impact factor: 5.128

2.  Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIIA Registry.

Authors:  María Asunción Esteve-Pastor; Martín Ruiz-Ortiz; Javier Muñiz; Inmaculada Roldán-Rabadán; Déborah Otero; Ángel Cequier; Vicente Bertomeu-Martínez; Lina Badimón; Manuel Anguita; Gregory Y H Lip; Francisco Marín
Journal:  Front Cardiovasc Med       Date:  2022-05-02

Review 3.  Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Authors:  Benjamin J R Buckley; Deirdre A Lane; Peter Calvert; Juqian Zhang; David Gent; C Daniel Mullins; Paul Dorian; Shun Kohsaka; Stefan H Hohnloser; Gregory Y H Lip
Journal:  J Clin Med       Date:  2022-06-30       Impact factor: 4.964

4.  Atrial fibrillation.

Authors: 
Journal:  Nat Rev Dis Primers       Date:  2016-03-31       Impact factor: 65.038

5.  Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke.

Authors:  Gregory Y H Lip; Deirdre A Lane; Radosław Lenarczyk; Giuseppe Boriani; Wolfram Doehner; Laura A Benjamin; Marc Fisher; Deborah Lowe; Ralph L Sacco; Renate Schnabel; Caroline Watkins; George Ntaios; Tatjana Potpara
Journal:  Eur Heart J       Date:  2022-07-07       Impact factor: 35.855

6.  Associations of anemia with death and major bleeding in patients with atrial fibrillation: A report from the Chinese Atrial Fibrillation Registry Study.

Authors:  Zhuxin Zhang; Chao Jiang; Liu He; Yu Bai; Jiahui Wu; Rong Hu; Qiang Lv; Man Ning; Li Feng; Ribo Tang; Caihua Sang; Deyong Long; Jianzeng Dong; Xin Du; Gregory Y H Lip; Changsheng Ma
Journal:  Clin Cardiol       Date:  2021-12-28       Impact factor: 2.882

7.  2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary.

Authors:  Tze-Fan Chao; Boyoung Joung; Yoshihide Takahashi; Toon Wei Lim; Eue-Keun Choi; Yi-Hsin Chan; Yutao Guo; Charn Sriratanasathavorn; Seil Oh; Ken Okumura; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2021-11-13       Impact factor: 5.249

8.  Fracture risks in patients with atrial fibrillation treated with different oral anticoagulants: a meta-analysis and systematic review.

Authors:  Xiaoping Xie; Yumeng Liu; Jiangbi Li; Feng Gu; Ke Zhang; Zhenjiang Sui; Jiting Zhang; Tiecheng Yu
Journal:  Age Ageing       Date:  2022-01-06       Impact factor: 10.668

9.  The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.

Authors:  Yuan Yao; Yutao Guo; Gregory Y H Lip
Journal:  JAMA Netw Open       Date:  2021-12-01

10.  Long-term risk of adverse outcomes according to atrial fibrillation type.

Authors:  Steffen Blum; Stefanie Aeschbacher; Michael Coslovsky; Pascal B Meyre; Philipp Reddiess; Peter Ammann; Paul Erne; Giorgio Moschovitis; Marcello Di Valentino; Dipen Shah; Jürg Schläpfer; Rahel Müller; Jürg H Beer; Richard Kobza; Leo H Bonati; Elisavet Moutzouri; Nicolas Rodondi; Christine Meyer-Zürn; Michael Kühne; Christian Sticherling; Stefan Osswald; David Conen
Journal:  Sci Rep       Date:  2022-02-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.